186 related articles for article (PubMed ID: 30349208)
1. A patient-reported, non-interventional, cross-sectional discrete choice experiment to determine treatment attribute preferences in treatment-naïve overactive bladder patients in the US.
Athavale A; Gooch K; Walker D; Suh M; Scaife J; Haber A; Hadker N; Dmochowski R
Patient Prefer Adherence; 2018; 12():2139-2152. PubMed ID: 30349208
[TBL] [Abstract][Full Text] [Related]
2. Older People's Preferences for Side Effects Associated with Antimuscarinic Treatments of Overactive Bladder: A Discrete-Choice Experiment.
Decalf VH; Huion AMJ; Benoit DF; Denys MA; Petrovic M; Everaert KCMM
Drugs Aging; 2017 Aug; 34(8):615-623. PubMed ID: 28656509
[TBL] [Abstract][Full Text] [Related]
3. Patient preference elicitation instrument, OABCare, to facilitate shared decision-making in the care of overactive bladder.
Chhatre S; Newman DK; Wein AJ; Jayadevappa R
Neurourol Urodyn; 2021 Mar; 40(3):791-801. PubMed ID: 33565118
[TBL] [Abstract][Full Text] [Related]
4. Preferences for antimuscarinic therapy for overactive bladder.
Swinburn P; Lloyd A; Ali S; Hashmi N; Newal D; Najib H
BJU Int; 2011 Sep; 108(6):868-73. PubMed ID: 21105989
[TBL] [Abstract][Full Text] [Related]
5. Treatments for overactive bladder: focus on pharmacotherapy.
Geoffrion R;
J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
[TBL] [Abstract][Full Text] [Related]
6. Comparing Discrete Choice Experiment with Swing Weighting to Estimate Attribute Relative Importance: A Case Study in Lung Cancer Patient Preferences.
Veldwijk J; Smith IP; Oliveri S; Petrocchi S; Smith MY; Lanzoni L; Janssens R; Huys I; de Wit GA; Groothuis-Oudshoorn CGM
Med Decis Making; 2024 Feb; 44(2):203-216. PubMed ID: 38178591
[TBL] [Abstract][Full Text] [Related]
7. Patient preferences for treating refractory overactive bladder in the UK.
Hashim H; Beusterien K; Bridges JF; Amos K; Cardozo L
Int Urol Nephrol; 2015 Oct; 47(10):1619-27. PubMed ID: 26347077
[TBL] [Abstract][Full Text] [Related]
8. Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder.
Tang DH; Colayco DC; Khalaf KM; Piercy J; Patel V; Globe D; Ginsberg D
BJU Int; 2014 Mar; 113(3):484-91. PubMed ID: 24528881
[TBL] [Abstract][Full Text] [Related]
9. Real-world treatment preferences among health care providers in the United States in selecting disease modifying therapies for patients with multiple sclerosis: a discrete choice experiment.
Bandari D; Adamson M; Bowman M; Gutierrez A; Athavale A; Oak B; Hadker N; Branco F; Geremakis C; Lewin JB; Shankar SL
J Med Econ; 2023; 26(1):1507-1518. PubMed ID: 37934412
[TBL] [Abstract][Full Text] [Related]
10. Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment.
Thomas C; Ailawadhi S; Popat R; Kleinman D; Ross MM; Gorsh B; Mulnick S; O'Neill A; Paka P; Hanna M; Krucien N; Molinari A; Gelhorn HL; Perera S
Front Med (Lausanne); 2023; 10():1271657. PubMed ID: 38076274
[TBL] [Abstract][Full Text] [Related]
11. The Prevalence of Overactive Bladder Symptoms in Women in Algeria, Egypt, Jordan and Lebanon: A Cross-Sectional Population-Based Survey.
Al Edwan G; Abdelazim MS; Salhab SE; Jamal YM; Soliman MA
Adv Ther; 2021 Feb; 38(2):1155-1167. PubMed ID: 33354738
[TBL] [Abstract][Full Text] [Related]
12. Patient Preferences for Preventive Migraine Treatments: A Discrete-Choice Experiment.
Mansfield C; Gebben DJ; Sutphin J; Tepper SJ; Schwedt TJ; Sapra S; Shah N
Headache; 2019 May; 59(5):715-726. PubMed ID: 30861110
[TBL] [Abstract][Full Text] [Related]
13. Assessment of treatment-seeking behavior and healthcare utilization in an international cohort of subjects with overactive bladder.
Jimenez-Cidre M; Costa P; Ng-Mak D; Sahai A; Degboe A; Smith CP; Tsai K; Herschorn S
Curr Med Res Opin; 2014 Aug; 30(8):1557-64. PubMed ID: 24762033
[TBL] [Abstract][Full Text] [Related]
14. Patient preferences and predicted relative uptake for targeted therapies in metastatic colorectal cancer: a discrete choice experiment.
Wong XY; Lim AQJ; Shen Q; Chia JWK; Chew MH; Tan WS; Wee HL
Curr Med Res Opin; 2020 Oct; 36(10):1677-1686. PubMed ID: 32609014
[TBL] [Abstract][Full Text] [Related]
15. Potential benefits of diagnosis and treatment on health outcomes among elderly people with symptoms of overactive bladder.
Lee LK; Goren A; Zou KH; Odell K; Russell D; Araiza AL; Luo X
Int J Clin Pract; 2016 Jan; 70(1):66-81. PubMed ID: 26662296
[TBL] [Abstract][Full Text] [Related]
16. Impact of overactive bladder on quality of life and resource use: results from Korean Burden of Incontinence Study (KOBIS).
Lee KS; Choo MS; Seo JT; Oh SJ; Kim HG; Ng K; Lee KJ; Tan JT; Kim JC
Health Qual Life Outcomes; 2015 Jun; 13():89. PubMed ID: 26113125
[TBL] [Abstract][Full Text] [Related]
17. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
[TBL] [Abstract][Full Text] [Related]
18. Understanding the elements of overactive bladder: questions raised by the EPIC study.
Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
[TBL] [Abstract][Full Text] [Related]
19. Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States.
Qin L; Luo X; Zou KH; Snedecor SJ
J Med Econ; 2016; 19(3):229-35. PubMed ID: 26488196
[TBL] [Abstract][Full Text] [Related]
20. Use of best-worst scaling to assess patient perceptions of treatments for refractory overactive bladder.
Beusterien K; Kennelly MJ; Bridges JF; Amos K; Williams MJ; Vasavada S
Neurourol Urodyn; 2016 Nov; 35(8):1028-1033. PubMed ID: 26370222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
